# Creative Realities, Inc.: financial statements, quarterly

CREX · Nasdaq · CIK 1356093 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/crex.md) · [Financials](/companies/crex/financials.md) · [Filings](/companies/crex/filings.md) · [Insiders](/companies/crex/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/crex/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [11.6](/filings/0001437749-24-034670.md) | [14.5 d](/filings/0001437749-25-007738.md) | [12.3](/filings/0001437749-25-016605.md) | [13.1](/filings/0001437749-25-026358.md) | [14.4](/filings/0001437749-25-034249.md) | [11.0 d](/filings/0001437749-26-012302.md) | [9.7](/filings/0001437749-26-017219.md) | [13.0](/filings/0001437749-26-027825.md) | [10.5](/filings/0001437749-25-034249.md) | [23.9 d](/filings/0001437749-26-012302.md) | [16.3](/filings/0001437749-26-017219.md) | [21.5](/filings/0001437749-26-027825.md) |
| Cost of revenue | $m | [6.3](/filings/0001437749-24-034670.md) | [7.0 d](/filings/0001437749-25-007738.md) | [6.5](/filings/0001437749-25-016605.md) | [6.3](/filings/0001437749-25-026358.md) | [7.9](/filings/0001437749-25-034249.md) | [6.1 d](/filings/0001437749-26-012302.md) | [5.3](/filings/0001437749-26-017219.md) | [8.0](/filings/0001437749-26-027825.md) | [5.8](/filings/0001437749-25-034249.md) | [12.5 d](/filings/0001437749-26-012302.md) | [10.8](/filings/0001437749-26-017219.md) | [13.2](/filings/0001437749-26-027825.md) |
| Gross profit | $m | [5.3](/filings/0001437749-24-034670.md) | [7.5 d](/filings/0001437749-25-007738.md) | [5.8](/filings/0001437749-25-016605.md) | [6.8](/filings/0001437749-25-026358.md) | [6.6](/filings/0001437749-25-034249.md) | [4.9 d](/filings/0001437749-26-012302.md) | [4.5](/filings/0001437749-26-017219.md) | [5.0](/filings/0001437749-26-027825.md) | [4.8](/filings/0001437749-25-034249.md) | [11.5 d](/filings/0001437749-26-012302.md) | [5.6](/filings/0001437749-26-017219.md) | [8.3](/filings/0001437749-26-027825.md) |
| Research and development | $m | [0.4](/filings/0001437749-23-031312.md) | [0.4 d](/filings/0001437749-24-008777.md) | [0.5](/filings/0001437749-24-015814.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [0.2](/filings/0001437749-24-034670.md) | [2.0 d](/filings/0001437749-25-007738.md) | [(0.1)](/filings/0001437749-25-016605.md) | [0.6](/filings/0001437749-25-026358.md) | [1.1](/filings/0001437749-25-034249.md) | [(0.7) d](/filings/0001437749-26-012302.md) | [(0.7)](/filings/0001437749-26-017219.md) | [(1.3)](/filings/0001437749-26-027825.md) | [(7.3)](/filings/0001437749-25-034249.md) | [0.5 d](/filings/0001437749-26-012302.md) | [(6.2)](/filings/0001437749-26-017219.md) | [(2.7)](/filings/0001437749-26-027825.md) |
| Interest expense | $m | [0.7](/filings/0001437749-23-031312.md) | [0.7 d](/filings/0001437749-24-008777.md) | [0.7](/filings/0001437749-24-015814.md) | [0.5](/filings/0001437749-25-026358.md) | [0.3](/filings/0001437749-25-034249.md) | [0.3 d](/filings/0001437749-26-012302.md) | [0.3](/filings/0001437749-26-017219.md) | [0.5](/filings/0001437749-26-027825.md) | [0.5](/filings/0001437749-25-034249.md) | [1.1 d](/filings/0001437749-26-012302.md) | [1.5](/filings/0001437749-26-017219.md) | [1.4](/filings/0001437749-26-027825.md) |
| Income tax | $m | [(0.0)](/filings/0001437749-24-034670.md) | [0.0 d](/filings/0001437749-25-007738.md) | [0.0](/filings/0001437749-25-016605.md) | [0.0](/filings/0001437749-25-026358.md) | [0.2](/filings/0001437749-25-034249.md) | [(0.1) d](/filings/0001437749-26-012302.md) | [0.1](/filings/0001437749-26-017219.md) | [(0.0)](/filings/0001437749-26-027825.md) | [(0.1)](/filings/0001437749-25-034249.md) | [1.2 d](/filings/0001437749-26-012302.md) | [(0.5)](/filings/0001437749-26-017219.md) | [(0.3)](/filings/0001437749-26-027825.md) |
| Net income | $m | [(1.9)](/filings/0001437749-24-034670.md) | [1.4 d](/filings/0001437749-25-007738.md) | [(0.1)](/filings/0001437749-25-016605.md) | [(0.6)](/filings/0001437749-25-026358.md) | [0.1](/filings/0001437749-25-034249.md) | [(2.8) d](/filings/0001437749-26-012302.md) | [3.4](/filings/0001437749-26-017219.md) | [(1.8)](/filings/0001437749-26-027825.md) | [(7.9)](/filings/0001437749-25-034249.md) | [(2.0) d](/filings/0001437749-26-012302.md) | [(7.5)](/filings/0001437749-26-027825.md) | [(3.9)](/filings/0001437749-26-027825.md) |
| Diluted EPS | $ per share | [(0.22)](/filings/0001437749-24-034670.md) | not reported | [(0.01)](/filings/0001437749-25-016605.md) | [(0.06)](/filings/0001437749-25-026358.md) | [0.01](/filings/0001437749-25-034249.md) | not reported | [0.32](/filings/0001437749-25-016605.md) | [(0.17)](/filings/0001437749-26-027825.md) | [(0.75)](/filings/0001437749-25-034249.md) | not reported | not reported | [(0.41)](/filings/0001437749-26-027825.md) |
| Basic EPS | $ per share | [(0.22)](/filings/0001437749-24-034670.md) | not reported | [(0.01)](/filings/0001437749-25-016605.md) | [(0.06)](/filings/0001437749-25-026358.md) | [0.01](/filings/0001437749-25-034249.md) | not reported | [0.32](/filings/0001437749-26-017219.md) | [(0.17)](/filings/0001437749-26-027825.md) | [(0.75)](/filings/0001437749-25-034249.md) | not reported | [(0.74)](/filings/0001437749-26-017219.md) | [(0.41)](/filings/0001437749-26-027825.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q3 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [8.4](/filings/0001437749-23-031312.md) | [2.9](/filings/0001437749-25-007738.md) | [2.9](/filings/0001437749-24-015814.md) | [4.1](/filings/0001437749-24-026573.md) | [0.9](/filings/0001437749-24-034670.md) | [1.0](/filings/0001437749-26-012302.md) | [1.1](/filings/0001437749-25-016605.md) | [0.6](/filings/0001437749-25-026358.md) | [0.3](/filings/0001437749-25-034249.md) | [1.6](/filings/0001437749-26-027825.md) | [1.8](/filings/0001437749-26-017219.md) | [10.7](/filings/0001437749-26-027825.md) |
| Current assets | $m | [17.5](/filings/0001437749-23-031312.md) | [18.6](/filings/0001437749-25-007738.md) | [16.3](/filings/0001437749-24-015814.md) | [17.5](/filings/0001437749-24-026573.md) | [16.0](/filings/0001437749-24-034670.md) | [14.5](/filings/0001437749-26-012302.md) | [16.9](/filings/0001437749-25-016605.md) | [13.1](/filings/0001437749-25-026358.md) | [17.0](/filings/0001437749-25-034249.md) | [33.5](/filings/0001437749-26-027825.md) | [26.1](/filings/0001437749-26-017219.md) | [34.9](/filings/0001437749-26-027825.md) |
| Total assets | $m | [69.7](/filings/0001437749-23-031312.md) | [70.8](/filings/0001437749-25-007738.md) | [68.2](/filings/0001437749-24-015814.md) | [69.6](/filings/0001437749-24-026573.md) | [67.6](/filings/0001437749-24-034670.md) | [65.2](/filings/0001437749-26-012302.md) | [67.0](/filings/0001437749-25-016605.md) | [63.7](/filings/0001437749-25-026358.md) | [61.3](/filings/0001437749-25-034249.md) | [151](/filings/0001437749-26-027825.md) | [138](/filings/0001437749-26-017219.md) | [143](/filings/0001437749-26-027825.md) |
| Current liabilities | $m | [19.7](/filings/0001437749-23-031312.md) | [20.2](/filings/0001437749-25-007738.md) | [38.7](/filings/0001437749-24-015814.md) | [26.7](/filings/0001437749-24-026573.md) | [27.5](/filings/0001437749-24-034670.md) | [26.2](/filings/0001437749-26-012302.md) | [13.7](/filings/0001437749-25-016605.md) | [13.0](/filings/0001437749-25-026358.md) | [16.5](/filings/0001437749-25-034249.md) | [39.3](/filings/0001437749-26-027825.md) | [35.6](/filings/0001437749-26-017219.md) | [38.6](/filings/0001437749-26-027825.md) |
| Total liabilities | $m | [42.3](/filings/0001437749-23-031312.md) | [41.9](/filings/0001437749-25-007738.md) | [39.4](/filings/0001437749-24-015814.md) | [41.3](/filings/0001437749-24-026573.md) | [39.3](/filings/0001437749-24-034670.md) | [39.8](/filings/0001437749-26-012302.md) | [37.1](/filings/0001437749-25-016605.md) | [34.2](/filings/0001437749-25-026358.md) | [39.4](/filings/0001437749-25-034249.md) | [102](/filings/0001437749-26-027825.md) | [97.1](/filings/0001437749-26-017219.md) | [95.3](/filings/0001437749-26-027825.md) |
| Long-term debt | $m | [10.6](/filings/0001437749-23-031312.md) | [9.8](/filings/0001437749-25-007738.md) | [0.0](/filings/0001437749-24-015814.md) | [13.6](/filings/0001437749-24-026573.md) | [10.7](/filings/0001437749-24-034670.md) | [13.0](/filings/0001437749-26-012302.md) | [22.6](/filings/0001437749-25-016605.md) | [19.3](/filings/0001437749-25-026358.md) | [21.2](/filings/0001437749-25-034249.md) | [39.5](/filings/0001437749-26-027825.md) | [43.0](/filings/0001437749-26-017219.md) | [41.2](/filings/0001437749-26-027825.md) |
| Current portion of debt | $m | [4.2](/filings/0001437749-23-031312.md) | [3.7](/filings/0001437749-25-007738.md) | [12.8](/filings/0001437749-24-015814.md) | [0.0](/filings/0001437749-24-026573.md) | [0.0](/filings/0001437749-24-034670.md) | [0.0](/filings/0001437749-26-012302.md) | [0.4](/filings/0001437749-25-016605.md) | [0.6](/filings/0001437749-25-026358.md) | [0.8](/filings/0001437749-25-034249.md) | [4.4](/filings/0001437749-26-027825.md) | [4.5](/filings/0001437749-26-017219.md) | [5.5](/filings/0001437749-26-027825.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [27.4](/filings/0001437749-24-034670.md) | [28.8](/filings/0001437749-26-012302.md) | [28.8](/filings/0001437749-25-026358.md) | [28.2](/filings/0001437749-25-034249.md) | [28.3](/filings/0001437749-25-034249.md) | [25.5](/filings/0001437749-26-027825.md) | [29.9](/filings/0001437749-26-027825.md) | [29.4](/filings/0001437749-26-027825.md) | [21.9](/filings/0001437749-25-034249.md) | [21.5](/filings/0001437749-26-027825.md) | [13.1](/filings/0001437749-26-027825.md) | [19.2](/filings/0001437749-26-027825.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [1,962 d](/filings/0001437749-24-034670.md) | [(3,139) d](/filings/0001437749-25-007738.md) | [1,938](/filings/0001437749-25-016605.md) | [2,268 d](/filings/0001437749-25-026358.md) | [544 d](/filings/0001437749-25-034249.md) | [(1,369) d](/filings/0001437749-26-012302.md) | [(2,449)](/filings/0001437749-26-017219.md) | [773](/filings/0001437749-25-026358.md) | [(1,607) d](/filings/0001437749-25-034249.md) | [(6,916) d](/filings/0001437749-26-012302.md) | [(1,723)](/filings/0001437749-26-017219.md) | [2,726 d](/filings/0001437749-26-027825.md) |
| Capital expenditure | $k | [68.0 d](/filings/0001437749-24-034670.md) | [19.0 d](/filings/0001437749-25-007738.md) | [6.0](/filings/0001437749-25-016605.md) | [2.0 d](/filings/0001437749-25-026358.md) | [1.0 d](/filings/0001437749-25-034249.md) | [2.0 d](/filings/0001437749-26-012302.md) | [8.0](/filings/0001437749-26-017219.md) | [101 d](/filings/0001437749-26-027825.md) | [101 d](/filings/0001437749-25-034249.md) | [96.0 d](/filings/0001437749-26-012302.md) | [183](/filings/0001437749-26-017219.md) | [2,269 d](/filings/0001437749-26-027825.md) |
| Dividends paid | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: not reported

## Shares

| Line item | Unit | Q2 FY2022 (2022-06-30) | period not labelled (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [7.2](/filings/0001437749-23-022050.md) | [7.3](/filings/0001437749-23-031312.md) | [7.4](/filings/0001437749-24-015814.md) | [7.4](/filings/0001437749-24-026573.md) | [8.7](/filings/0001437749-24-034670.md) | [10.4](/filings/0001437749-25-016605.md) | [10.4](/filings/0001437749-25-026358.md) | [0.0](/filings/0001437749-25-034249.md) | [10.4](/filings/0001437749-25-016605.md) | [10.5](/filings/0001437749-26-027825.md) | [0.0](/filings/0001437749-25-034249.md) | [10.6](/filings/0001437749-26-027825.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 13,526,506 at 2026-08-11, from the cover of the [10-Q filed 2026-08-14](/filings/0001437749-26-027825.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:37 ET. No prices; not investment advice.